Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer
MADRID -- Immunotherapy, chemotherapy, and a PARP inhibitor in the first line improved progression-free survival…
Browsing Tag
Endometrial
FDA OKs New Frontline Endometrial Cancer Regimen, First in Decades
The FDA approved the immune checkpoint inhibitor dostarlimab (Jemperli) plus…
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus…
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and Drug Administration approval…
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center…
The ‘Four Buckets’ of Breakthroughs in Endometrial Cancer
At the American Society of Clinical Oncology annual meeting, several important abstracts on…
Platform Trial Looks at Endometrial Cancer Treatment Combinations
A phase II study is investigating olaparib (Lynparza), cediranib (Recentin), durvalumab…
A Changing Landscape in First-Line Endometrial Cancer
The buzz created by two phase III studies testing immunotherapy in advanced or recurrent…
Three Areas of Promise in Endometrial Cancer
At the American Society of Clinical Oncology annual meeting, several important abstracts on…
Watch for MLH1 Methylation in Younger Endometrial, Colorectal Cancer Patients
High-risk constitutional MLH1 methylation underlies a significant proportion of early-onset…
Hysterectomy Ultimately Needed After 1 in 8 Endometrial Ablations
Hysterectomy rates can be expected to rise slowly in the months and years following endometrial ablation,…